Epizyme Inc ((EPZM)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Epizyme Inc. is conducting a study titled ‘Tazemetostat Rollover Study (TRuST): An Open-Label, Rollover Study’ to evaluate the long-term safety of tazemetostat in adults who have previously participated in a tazemetostat clinical trial. The study aims to ensure continued access to tazemetostat for patients who have shown clinical benefit without unacceptable toxicity or tumor progression.
The intervention being tested is tazemetostat, a selective small molecule inhibitor of the EZH2 enzyme, used to treat various diseases. Participants will continue their previous dosage and schedule of tazemetostat, with the study focusing on long-term safety, time to treatment failure, and overall survival.
This interventional study employs a single-group assignment model with no masking, primarily aimed at treatment. It is an open-label, multicenter, global study, allowing participants to continue receiving tazemetostat as per their prior study protocol.
The study began on August 30, 2016, with its last update submitted on July 31, 2025. These dates are crucial for tracking the study’s progress and ensuring transparency in its ongoing status.
The continuation of this study could positively influence Epizyme Inc.’s stock performance by reinforcing investor confidence in the long-term viability of tazemetostat. As the study progresses, it may also impact the competitive landscape, particularly if results demonstrate significant safety and efficacy.
The study is currently active but not recruiting, with further details available on the ClinicalTrials portal.